Observational studyUnited European gastroenterology journal2026

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.

Louis Calméjane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.